One Small Step . . .*

Ileana L. Piña, MD, MPH

Heart failure (HF) cardiologists have long been caring for patients who, after having triumphed over a malignancy, now face a difficult challenge due to the HF symptoms of anthracycline-induced cardiomyopathy (AIC). HF is often called the “cancer of the heart” due to its overall mortality. As aggressively as HF specialists practice using medical and device therapies, some patients with AIC may stabilize and/or improve. However, many continue to deteriorate and become candidates for advanced therapies such as heart transplantation or mechanical assistance (1). Even more tragic is the younger age of the AIC population, many of them women who have survived a breast cancer diagnosis already. Heart failure due to AIC is not an ordinary nonischemic cardiomyopathy and is comparable in survival to HIV or to infiltrative myocardial disease, with a 3-times-higher mortality than idiopathic cardiomyopathy (2). Through the past 10 years, much time has been spent describing the pathological changes of AIC, including recent basic science reports of early loss of cardiac mass leading to myocardial atrophy, which may be a very early marker of AIC (3). Furthermore, efforts toward early identification of AIC have included the recognition of risk factors, such as hypertension, and tracking damage and response with biomarkers, such as troponin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) (4,5). Pre-symptom detection strategies have been extended into echocardiography with measurement of global longitudinal strain incorporated into the imaging guidelines (6). On the therapeutic side, there have been a multitude of studies reporting on pharmacologic therapy with the same medications that the American College of Cardiology/American Heart Association guidelines for HF call “ guideline-directed medical therapy” (GDMT) (7). The results have been variable, with agents such as angiotensin-converting enzyme inhibitors (8,9), beta blockers, and mineralocorticoid receptor antagonists (10). For example, a meta-analysis of carvedilol reported lower rates of left ventricular dysfunction and less deterioration of ejection fraction as primary prevention (11). Overall, however, these agents, especially angiotensin-converting enzyme inhibitors, seem to be protective post-chemotherapy, with the ongoing discussions agreeing on their usefulness early in the course of AIC (4). Unfortunately, many patients may reach the HF specialists long after the AIC has evolved and symptoms have called attention to its presence.

In the midst of this truly unmet need is the promise of cell therapy, with encouraging results in preclinical and early clinical trials of bone marrow–derived mesenchymal stromal cells (allo-MSCs) with low immunogenicity. The potential for cell therapy to be beneficial in AIC would address some of the pathological changes, including the replacement of myocytes and fibrosis, among others. Enter Bolli et al. (12) in this issue of JACC: CardioOncology, who boldly present the SENECA (Stem Cell Injection in Cancer Survivors) trial from the Cardiovascular Cell Therapy Research Network of the National Institutes of Health (12). The primary purpose of this first-in-human phase 1 study was judiciously chosen to test the safety and feasibility of allo-MSCs injected transendocardially. The results of this study would inform

*Editorials published in JACC: CardioOncology reflect the views of the author and do not necessarily represent the views of JACC: CardioOncology of the American College of Cardiology.

From Wayne State University, Detroit, Michigan; and Central Michigan University, Midland, Michigan, USA.

The author attests they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: CardioOncology author instructions page.
phase 2 and 3 trials. The study design was elegant, using an open lead-in phase followed by a random- ized controlled design, and for this step, the inves- tigators should be congratulated. Although not powered for outcomes and measures of cardiac function, Bolli et al. nonetheless wisely collected a group of parameters that will be informative for future studies and serve as hypotheses generating, such as magnetic resonance imaging (MRI) measures, NT-proBNP, a functional measure with the 6-minute walk, and the ever-important health-related quality of life (HRQoL) representing patient-reported outcomes using a standardized instrument. If there were positive signals, these could be amplified in a follow- up trial. The ability to collect MRI data would be challenging, given the prospect that a large number of patients with AIC would have qualified for an implantable cardioverter-defibrillator. However, using an imaging protocol developed by the MRI Core Lab at Johns Hopkins and training sites for safety, the study was able to image 94% of participants at the 12-month visit, although 59% had MRI-noncompatible devices. Other safety-based processes included only patients with >2 years of cancer-free survival to minimize chances of recurrence, the exclusion of New York Heart Association functional class I and IV and more recently diagnosed individuals. 

As expected, more than one-half of the patients were women at ages younger than that of the average patient with HF in the United States. With an ejection fraction of approximately 33%, this group was indeed in the HF with reduced ejection fraction category and eligible for GDMT. The patients were well medicated by percentage on therapy, although doses were not reported, and a large percentage had implantable cardioverter-defibrillators. Future trials should include GDMTs to test whether allo-MSCs will succeed with concomitant current quality care. The injections were successfully deployed in 97% of the patients with no new tumors detected and without evidence of immune reaction to the injections. Serious adverse events were evenly balanced between treatment and control with more >20% being cardiac. There was 1 death in the treated group due to progressive HF and 7 hospitalizations for 5 patients with worsening HF. Clinical outcomes were not unexpected and were similar between groups, with the exception of a borderline 6-minute walk finding and HRQoL results favoring the allo-MSC group. Thus, the trial was successful and met the feasibility and safety primary objective.

Beyond the results, and as in most clinical trials, there are observations worthy of note and that are highly informative:

1. The diverse racial and ethnic patient recruitment is worthy of praise, with 23% Black and 13% Hispanic participants. It is hoped that this diverse patient group is equally represented in phase 2 studies and beyond.
2. More than 40% of patients had hypertension, a risk factor for the development of AIC. The length of time between the original chemotherapy and the current study is impressive and gives credence to the need for heightened screening and follow-up many years beyond when chemotherapy ends.
3. Although primarily a New York Heart Association functional class II population, nearly 50% had been previously hospitalized for HF, and 23% had an emergency department visit for HF, with 38% reporting ventricular arrhythmia. Furthermore, the ventricular volumes were abnormal (13) and the NT-proBNP levels were elevated, indicative of the appropriate population to be studied.
4. The 6-minute walk results were also abnormal and had wide variability. Future trials will need a large number of participants recruited to capture meaningful differences.
5. The improvement in HRQoL is certainly intriguing if patients in fact feel better before changes seen in MRI measurements. It will be important to explore which portions of the instrument improved, for example, function, symptoms, or quality of life. This finding will need to be confirmed in a larger future trial, but its collection is in keeping with the current emphasis on patient-reported outcomes.

In summary, this is an important step to the resolu- tion of an undesired effect of chemotherapy that has been deeply concerning to both oncologists and cardiologists, as well as patients and their loved ones. Although it had a small number of participants, this study can be considered a landmark with hope. A small step in the field, it may become a large step for many more in the future.

ACKNOWLEDGMENT Dedicated to Jamiah, who triumphed over cancer at age 9 years only to succumb to AIC 12 years later.

AUTHOR DISCLOSURES

Dr. Piña has reported that she has no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr. Ileana L. Piña, Wayne State University, 2627 Fairmount Boulevard, Cleveland Heights, Ohio 44106. E-mail: ilppina@aol.com. Twitter: @ilppina.
REFERENCES

1. Thomas GR, McDonald MA, Day J, et al. A matched cohort study of patients with end-stage heart failure from anthracycline-induced cardiomyopathy requiring advanced cardiac support. Am J Cardiol 2016;118:1539-44.

2. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-84.

3. Willis MS, Parry TL, Brown DI, et al. Doxorubicin exposure causes subacute cardiac atrophy dependent on the striated muscle-specific ubiquitin ligase MuRF1. Circ Heart Fail 2019;12:e005234.

4. Hamo CE, Bloom MW, Cardinale D, et al. Cancer therapy-related cardiac dysfunction and heart failure: part 2: prevention, treatment, guidelines, and future directions. Circ Heart Fail 2016;9: e002843.

5. Bloom MW, Hamo CE, Cardinale D, et al. Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail 2016;9: e002661.

6. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;15:1063-93.

7. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-239.

8. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-81.

9. Civelli M, Cardinale D, Martinoni A, et al. Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. Int J Cardiol 2006;111:120-6.

10. Akpek M, Ozdogru I, Sahin O, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 2015;17:81-9.

11. Kheiri B, Abdalla A, Osman M, et al. Meta-analysis of carvedilol for the prevention of anthracycline-induced cardiotoxicity. Am J Cardiol 2018;122:1959-64.

12. Bolli R, Perin EC, Willerson J, et al. Allogeneic mesenchymal cell therapy in anthracycline-induced cardiomyopathy heart failure patients: the CCTRN SENECA trial. J Am Coll Cardiol CardioOnc 2020;2:581-95.

13. Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, et al. Normal values for cardiovascular magnetic resonance in adults and children. J Cardiovasc Magn Reson 2015;17:29.

KEY WORDS cardiac repair, cardio-oncology, chemotherapy, heart failure, stem cells